Legalize / United Kingdom / Northern Ireland / Ni-Statutory-Rule

The Social Security (Industrial Injuries) (Prescribed Diseases) (Amendment) Regulations (Northern Ireland) 2003

Type Ni-Statutory-Rule

Publication 2003-02-11

Last updated 2015-03-16

State In force

Jurisdiction Northern Ireland

Department Government Printer for Northern Ireland

Source legislation.gov.uk

PDF Download

articles Not indexed

Reform history JSON API

Made: 11th February 2003

Coming into operation: 17th March 2003

The Department for Social Development, in exercise of the powers conferred by sections 108(2) and (4), 109(2) and (3) and 171(1) to (4) of the Social Security Contributions and Benefits (Northern Ireland) Act 1992[^f00001], and now vested in it[^f00002], and of all other powers enabling it in that behalf, hereby makes the following Regulations:

Citation and commencement

1

These Regulations may be cited as the Social Security (Industrial Injuries) (Prescribed Diseases) (Amendment) Regulations (Northern Ireland) 2003 and shall come into operation on 17th March 2003.

2

(1) The Social Security (Industrial Injuries) (Prescribed Diseases) Regulations (Northern Ireland) 1986[^f00003] shall be amended in accordance with paragraphs (2) to (4) of this regulation.

(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(3) In regulations 7(1)(b)[^f00006] (recrudescence) and 8(1) (workmen’s compensation cases) the words “in the manner provided in Part X of the Adjudication Regulations” shall be omitted.

(4) In Part I of Schedule 1[^f00007] (list of prescribed diseases and the occupations for which they are prescribed) –

(a) the entries relating to prescribed diseases C8, C9, C10, C11, C14, C15 and C28[^f00008] (conditions due to chemical agents) shall be omitted;

(b) in the entry relating to prescribed disease C1 for the entry in the first column there shall be substituted –

C1.	aAnaemia with a haemoglobin concentration of 9g/dL or less, and a blood film showing punctate basophilia; }bperipheral neuropathy; }ccentral nervous system toxicity. }

C2.	Central nervous system toxicity characterised by parkinsonism.

(d) for the entry relating to prescribed disease C4 there shall be substituted –

C4.	Primary carcinoma of the bronchus or lung.	Exposure to the fumes, dust or vapour of arsenic, a compound of arsenic or a substance containing arsenic.

(e) for the entry relating to prescribed disease C5 there shall be substituted –

C5A.	Central nervous system toxicity characterised by tremor and neuropsychiatric disease.	Exposure to mercury or inorganic compounds of mercury for a period of, or periods which amount in aggregate to, 10 years or more.
C5B.	Central nervous system toxicity characterised by combined cerebellar and cortical degeneration.	Exposure to methylmercury.

(f) for the entry relating to prescribed disease C6 there shall be substituted –

C6.	Peripheral neuropathy.	The use or handling of, or exposure to, carbon disulphide (also called carbon disulfide).

(g) for the entry relating to prescribed disease C7 there shall be substituted –

C7.	Acute non-lymphatic leukaemia.	Exposure to benzene.

(h) for the entry relating to prescribed disease C12 there shall be substituted –

C12.	aPeripheral neuropathy; }bcentral nervous system toxicity. }	Exposure to methyl bromide (also called bromomethane).

(i) for the entry relating to prescribed disease C13 there shall be substituted –

C13.	Cirrhosis of the liver.	Exposure to chlorinated naphthalenes.

(j) for the entry relating to prescribed disease C16 there shall be substituted –

C16.	aNeurotoxicity; }bcardiotoxicity. }	Exposure to the dust of gonioma kamassi.

(k) for the entry relating to prescribed disease C17 there shall be substituted –

C17.	Chronic beryllium disease.	Inhalation of beryllium or a beryllium compound.

(l) for the entry relating to prescribed disease C18 there shall be substituted –

C18.	Emphysema.	Inhalation of cadmium fumes for a period of, or periods which amount in aggregate to, 20 years or more.

(m) for the entry relating to prescribed disease C19 there shall be substituted –

C19.	aPeripheral neuropathy; }bcentral nervous system toxicity. }	Exposure to acrylamide.

(n) in the entry relating to prescribed disease C20 for the entry in the second column there shall be substituted –

Exposure to quinone or hydroquinone.

(o) for the entry relating to prescribed disease C21 there shall be substituted –

C21.	Primary carcinoma of the skin.	Exposure to arsenic or arsenic compounds, tar, pitch, bitumen, mineral oil (including paraffin) or soot.

(p) for the entry relating to prescribed disease C22 there shall be substituted –

C22.	aPrimary carcinoma of the mucous membrane of the nose or paranasal sinuses; }bprimary carcinoma of the bronchus or lung. }	Work before 1950 in the refining of nickel involving exposure to oxides, sulphides or water-soluble compounds of nickel.

(q) for the entry relating to prescribed disease C23 there shall be substituted –

C23.	Primary neoplasm of the epithelial lining of the urinary tract.	aThe manufacture of 1-naphthylamine, 2-naphthylamine, benzidine, auramine, magenta or 4-aminobiphenyl (also called biphenyl-4-ylamine);bwork in the process of manufacturing methylene-bis-orthochloroaniline (also called MbOCA) for a period of, or periods which amount in aggregate to, 12 months or more;cexposure to 2-naphthylamine, benzidine, 4-aminobiphenyl (also called biphenyl-4-ylamine) or salts of those compounds otherwise than in the manufacture of those compounds;dexposure to orthotoluidine, 4-chloro- 2-methylaniline or salts of those compounds; oreexposure for a period of, or periods which amount in aggregate to, 5 years or more, to coal tar pitch volatiles produced in aluminium smelting involving the Soderberg process (that is to say, the method of producing aluminium by electrolysis in which the anode consists of a paste of petroleum coke and mineral oil which is baked in situ).

(r) for the entry relating to prescribed disease C24 there shall be substituted –

C24.	aAngiosarcoma of the liver; }bacro-osteolysis characterised by – }ilytic destruction of the terminal phalanges }iiin Raynaud’s phenomenon, the exaggerated vasomotor response to cold causing intense blanching of the digits, and }iiisclerodermatous thickening of the skin; }cliver fibrosis. }	Exposure to vinyl chloride monomer in the manufacture of polyvinyl chloride.

(s) for the entry relating to prescribed disease C25 there shall be substituted –

C25.	Vitiligo.	The use or handling of, or exposure to paratertiary-butylphenol (also called 4-tert-butylphenol), paratertiary-butylcatechol (also called 4-tert-butylcatechol), para-amylphenol (also called p-pentyl phenol isomers), hydroquinone, monobenzyl ether of hydroquinone (also called 4-benzyloxyphenol) or mono-butyl ether of hydroquinone (also called 4-butoxyphenol).

(t) for the entry relating to prescribed disease C26[^f00009] there shall be substituted –

C26.	aLiver toxicity; }bkidney toxicity. }	The use or handling of, or exposure to, carbon tetrachloride (also called tetrachloromethane).

(u) for the entry relating to prescribed disease C27 there shall be substituted –

C27.	Liver toxicity.	The use or handling of, or exposure to, trichloromethane (also called chloroform).

(v) for the entry relating to prescribed disease C29 there shall be substituted –

C29.	Peripheral neuropathy.	The use or handling of, or exposure to, n-hexane or n-butyl methyl ketone.

(w) for the entry relating to prescribed disease C30[^f00010] there shall be substituted –

C30.	aDermatitis; }bulceration of the mucous membrane or the epidermis. }	The use or handling of, or exposure to, chromic acid, chromates or dichromates.

Transitional provision

3

(1) Regulation 2(2) and (4) shall not apply –

(a) to a period of assessment which relates to a claim which is made before the commencement date;

(b) to a period of assessment which relates to a claim which is made within 3 months after the commencement date in respect of a period which began before the commencement date; or

(c) where a person suffers from an attack of a disease and under regulation 7 of the Social Security (Industrial Injuries) (Prescribed Diseases) Regulations (Northern Ireland) 1986 (recrudescence) the attack is a recrudescence of a disease for which a claim was made before the commencement date (or within 3 months after the commencement date in respect of a period which began before the commencement date).

(2) For the purposes of this regulation –

(a) “commencement date” means the date on which these Regulations come into operation;

(b) the date on which a claim is made is the date on which the claim is made or treated as made in accordance with the Social Security (Claims and Payments) Regulations (Northern Ireland) 1987[^f00011]; and

(c) a period of assessment which begins on the day following the end of a preceding period of assessment, shall be treated as a continuation of the preceding period of assessment.

Revocation

4

The following regulations are hereby revoked –

(a) regulation 3(2) of, and the Schedule to, the Social Security (Industrial Injuries) (Prescribed Diseases) (Amendment No. 2) Regulations (Northern Ireland) 1987[^f00012];

(b) regulation 6(3) of the Social Security (Industrial Injuries) (Prescribed Diseases) (Amendment) Regulations (Northern Ireland) 1993[^f00013]; and

(c) regulation 3(3)(c) of the Social Security (Industrial Injuries and Diseases) (Miscellaneous Amendments) Regulations (Northern Ireland) 1996[^f00014].

Signed

Sealed with the Official Seal of the Department for Social Development on 11th February 2003.

John O'Neill — Senior Officer of the — Department for Social Development

Explanatory note

(This note is not part of the Regulations.)

Regulation 2 of these Regulations makes amendments to the Social Security (Industrial Injuries) (Prescribed Diseases) Regulations (Northern Ireland) 1986 –

to remove 20 specified diseases from the presumption that they are due to the nature of the specified employment;

to remove references to a determination in the manner provided by Part X of the Social Security (Adjudication) Regulations (Northern Ireland) 1984; and

to remove references to 7 diseases due to chemical agents and change the entries for other diseases due to chemical agents.

Regulation 3 makes transitional provision so that the amendments both to the Schedule of prescribed diseases and to the presumption as to the cause of the disease do not apply in respect of claims made, or treated as made, before these Regulations come into operation.

Regulation 4 makes consequential revocations.

These Regulations correspond to provision contained in Regulations made by the Secretary of State for Work and Pensions in relation to Great Britain and accordingly, by virtue of section 149(3) of, and paragraph 7 of Schedule 5A to, the Social Security Administration (Northern Ireland) Act 1992 (c. 8), are not subject to the requirement of section 149(2A) of that Act for prior reference to the Industrial Injuries Advisory Council.

These Regulations do not impose a charge on business.

Footnotes

[^f00001]: 1992 c. 7; section 109(2) was amended by paragraph 47 of Schedule 6 to the Social Security (Northern Ireland) Order 1998 (S.I. 1998/1506 (N.I. 10)) and section 171(2) was amended by paragraph 28(2) of Schedule 3 to the Social Security Contributions (Transfer of Functions, etc.) (Northern Ireland) Order 1999 (S.I. 1999/671)

[^f00002]: See Article 8(b) of S.R. 1999 No. 481

[^f00003]: S.R. 1986 No. 179; relevant amending regulations are S.R. 1987 No. 454, S.R. 1989 No. 319, S.R. 1993 Nos. 148 and 350 and S.R. 1996 No. 57

[^f00007]: Relevant amending regulations are S.R. 1987 No. 454, S.R. 1993 No. 148 and S.R. 1996 No. 57

[^f00008]: Prescribed disease C28 was inserted by the Schedule to S.R. 1987 No. 454

[^f00009]: Prescribed diseases C26, C27 and C29 were inserted by regulation 3(2) of, and the Schedule to, S.R. 1987 No. 454

[^f00010]: Prescribed disease C30 was inserted by regulation 3(3)(c) of S.R. 1996 No. 57

[^f00011]: S.R. 1987 No. 465; relevant amending regulations are S.R. 1992 No. 83, S.R. 1996 No. 354, S.R. 1997 No. 156, S.R. 2000 Nos. 215 and 365, S.R. 2001 Nos. 175 and 176 and S.R. 2002 No. 67

[^f00012]: S.R. 1987 No. 454

[^f00013]: S.R. 1993 No. 148

[^f00014]: S.R. 1996 No. 57

Editorial notes

[^key-bafe9478dbcf7792b624026068f07814]: Reg. 1 in operation at 17.3.2003, see reg. 1

[^key-3f89cc63b5de6fddb74f5890233767f9]: Reg. 2 in operation at 17.3.2003, see reg. 1

[^key-b85ebbb3e0f7cafb9951d10c180eb01a]: Reg. 3 in operation at 17.3.2003, see reg. 1

[^key-3fe94fab45ce801774e0f6a52107b713]: Reg. 4 in operation at 17.3.2003, see reg. 1

Reading this document does not replace reading the official text published on legislation.gov.uk. Contains public sector information licensed under the Open Government Licence v3.0. We assume no responsibility for any inaccuracies arising from the conversion of the original CLML XML to this format.

This text is published under legislation.gov.uk's own terms of reuse, not a Legalize or public-domain licence. legislation.gov.uk
Open Government Licence v3.0 (attribution required)
© Crown and database right. Derived from content available under the Open Government Licence v3.0 from legislation.gov.uk.